Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) Director Arthur A. Levin sold 5,000 shares of Avidity Biosciences stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $45.19, for a total transaction of $225,950.00. Following the sale, the director now owns 14,830 shares in the company, valued at approximately $670,167.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Avidity Biosciences Stock Performance
Shares of RNA traded up $0.15 during midday trading on Wednesday, hitting $45.02. 1,584,050 shares of the stock traded hands, compared to its average volume of 1,329,024. Avidity Biosciences, Inc. has a 1-year low of $4.82 and a 1-year high of $48.80. The firm has a market capitalization of $4.31 billion, a PE ratio of -15.02 and a beta of 0.90. The business’s 50 day moving average price is $42.48 and its two-hundred day moving average price is $29.80.
Avidity Biosciences (NASDAQ:RNA – Get Free Report) last posted its quarterly earnings data on Friday, August 9th. The biotechnology company reported ($0.65) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.11. Avidity Biosciences had a negative net margin of 2,381.82% and a negative return on equity of 32.89%. The business had revenue of $2.05 million during the quarter, compared to the consensus estimate of $7.09 million. As a group, equities research analysts forecast that Avidity Biosciences, Inc. will post -2.93 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on RNA
Institutional Investors Weigh In On Avidity Biosciences
Several hedge funds and other institutional investors have recently bought and sold shares of RNA. Nisa Investment Advisors LLC raised its position in Avidity Biosciences by 15,900.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,200 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 3,180 shares in the last quarter. Mutual of America Capital Management LLC increased its holdings in shares of Avidity Biosciences by 11.4% in the 4th quarter. Mutual of America Capital Management LLC now owns 149,202 shares of the biotechnology company’s stock valued at $1,350,000 after purchasing an additional 15,245 shares during the period. Daiwa Securities Group Inc. increased its holdings in shares of Avidity Biosciences by 43.3% in the 4th quarter. Daiwa Securities Group Inc. now owns 10,537 shares of the biotechnology company’s stock valued at $95,000 after purchasing an additional 3,182 shares during the period. J.W. Cole Advisors Inc. acquired a new position in shares of Avidity Biosciences in the 4th quarter valued at about $283,000. Finally, abrdn plc bought a new stake in shares of Avidity Biosciences in the 4th quarter valued at approximately $1,171,000.
Avidity Biosciences Company Profile
Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.
Read More
- Five stocks we like better than Avidity Biosciences
- 3 Warren Buffett Stocks to Buy Now
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- 3 Best Fintech Stocks for a Portfolio Boost
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- What is a Bond Market Holiday? How to Invest and Trade
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Avidity Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avidity Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.